NONOF NOVO NORDISK A/S

添加自選

84.748
-18.327-17.78%

延時15分鐘行情收盤價 12/20 16:00 (美東)

3763.95億總市值28.59市盈率TTM

關於NOVO NORDISK A/S公司

諾和諾德擁有全球約三分之一的品牌糖尿病治療市場，是全球領先的糖尿病護理產品供應商。該公司總部位於丹麥，生產和銷售各種人用和現代胰島素、可注射糖尿病治療藥物（例如 GLP-1 療法）、口服抗糖尿病藥物和肥胖症治療藥物。諾和諾德還有一個生物製藥部門（約佔收入的 10%），專門從事血友病和其他疾病的蛋白質療法。

公司介紹

公司代碼NONOF

公司名稱NOVO NORDISK A/S

上市日期1981/07/09

成立日期1931

CEOMr. Lars Fruergaard Jorgensen

所屬市場粉單

員工數量64319

年結日12-31

公司地址Novo Allé 1

城市Bagsv?rd

省份首都地區

國家丹麥

郵編2880

電話45-44-44-88-88

網址http://www.novonordisk.com

董事高管

姓名
職務
年薪

Lars Fruergaard Jorgensen
Chief Executive Officer and President
--

Karsten Munk Knudsen
Executive Vice President and Chief Financial Officer
2640.00萬

Marcus Schindler, PhD
Executive Vice President, Research and Early Development and Chief Scientific Officer
2360.00萬

Ludovic Helfgott
Executive Vice President, Rare Disease
220.00萬

Maziar Mike Doustdar
Executive Vice President, International Operations
220.00萬

Doug Langa
Executive Vice President, North America Operations
220.00萬

Martin Holst Lange
Executive Vice President, Development
2340.00萬

Henrik Ehlers Wulff
Executive Vice President, Product Supply, Quality Assurance, Digital Data and IT
2590.00萬

Camilla Sylvest
Executive Vice President, Commercial Strategy and Corporate Affairs
2340.00萬

Helge Lund
Chairman of the Board
390.00萬

Henrik Poulsen
Vice Chairman of the Board
240.00萬

Liselotte Hyveled
Director
110.00萬

Elisabeth Dahl Christensen
Director
110.00萬

Thomas Rantzau
Director
110.00萬

Mette Bojer Jensen
Director
130.00萬

Kasim Kutay
Director
130.00萬

Dr. Sylvie Gregoire,Pharm.D.
Independent Director
200.00萬

Andreas Fibig
Independent Director
140.00萬

Christina Law
Independent Director
170.00萬

Laurence Debroux
Independent Director
210.00萬

Dr. Martin W. Mackay, PhD
Independent Director
180.00萬

Tania Sabroe
Executive Vice President, People and Organisation
220.00萬

David Moore
Executive Vice President, Corporate Development
220.00萬

熱議

美股

綜合熱度

暫無數據